Traditional LCA tumor markers, such as Carbohydrate Antigen 125 (CA125) and Neuron-Specific Enolase (NSE), are believed to be useful for monitoring the efficacy of immunotherapy in LCA patients. The gene discussed is ENO2; the disease is Leber congenital amaurosis.